Prevalence of Disability 2.7 Percent at U.S. Medical Schools

Share this content:
Prevalence of Disability 2.7 Percent at U.S. Medical Schools
Prevalence of Disability 2.7 Percent at U.S. Medical Schools

WEDNESDAY, Dec. 7, 2016 (HealthDay News) -- The prevalence of disability is 2.7 percent among medical students at U.S. allopathic medical schools, according to a research letter published in the Dec. 6 issue of the Journal of the American Medical Association, a theme issue of medical education.

Lisa M. Meeks, Ph.D., from the University of California in San Francisco, and Kurt R. Herzer, Ph.D., from the Johns Hopkins School of Medicine in Baltimore, examined the prevalence of all disabilities and the accommodations in use at allopathic medical schools. An electronic, web-based survey was sent to institutionally designated disability administrators from December 2014 through February 2016.

Overall, 91 of the 133 eligible medical schools completed the survey, and 89 reported complete data and were included in analyses. The researchers identified 1,547 students with disabilities, representing 2.7 percent of the total enrollment (range, 0 to 12 percent). A total of 97.7 percent of these students received accommodations. The most common disability was attention-deficit/hyperactivity disorder (ADHD; 33.7 percent), followed by learning disabilities and psychological disabilities (21.5 and 20.0 percent, respectively). Mobility and sensory disabilities were seen less frequently.

"The preponderance of students with ADHD, learning disabilities, and psychological disabilities suggests that these disability subtypes should be included in future research efforts, such as studies assessing the performance of appropriately accommodated students," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »